Art

J-GLOBAL ID：201902252735775339   Reference number：19A0365851

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

進行肝細胞癌およびα-フェトプロテイン濃度増加(REACH-2)患者におけるソラフェニブ後のラムコリマブ:無作為化二重盲検プラセボ対照第3相試験【JST・京大機械翻訳】

Author (28)： Zhu Andrew X (Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA) ,  Kang Yoon-Koo (Asan Medical Center, University of Ulsan, Seoul, South Korea) ,  Yen Chia-Jui (Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Tainan, Taiwan) ,  Yen Chia-Jui (College of Medicine, National Cheng Kung University, Tainan, Taiwan) ,  Finn Richard S (Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA) ,  Galle Peter R (University Medical Center, Mainz, Germany) ,  Llovet Josep M (Icahn School of Medicine at Mount Sinai, New York, NY, USA) ,  Llovet Josep M (Institut d’Investigations Biomediques, August Pi i Sunyer-Hospital Clinic Barcelona, Barcelona, Spain) ,  Assenat Eric (CHU de Montpellier, Montpellier, France) ,  Brandi Giovanni (University Hospital S Orsola, Bologna, Italy) ,  Pracht Marc (Centre Eugene Marquis, Rennes, France) ,  Lim Ho Yeong (Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea) ,  Rau Kun-Ming (Chang Gung Memorial Hospital-Kaohsiung Branch, Kaohsiung City, Taiwan) ,  Rau Kun-Ming (Hematology-Oncology Department, E-Da Cancer Hospital, Kaohsiung, Taiwan) ,  Motomura Kenta (Aso Iizuka Hospital-Hepatology, Iizuka, Fukuoka, Japan) ,  Ohno Izumi (National Cancer Center Hospital East-Hepatobiliary and Pancreatic Oncology, Kashiwa, Chiba, Japan) ,  Merle Philippe (Hopital de la Croix Rousse, Lyon, France) ,  Daniele Bruno (Azienda Ospedaliera G Rummo, Benevento, Benevento, Italy) ,  Daniele Bruno (Ospedale del Mare, Naples, Italy) ,  Shin Dong Bok (Gachon University Gil Medical Center, Incheon, South Korea) ,  Gerken Guido (Universtitaetsklinikum Essen AoR, Essen, North Rhine-Westphalia, Germany) ,  Borg Christophe (University Hospital of Besancon, Besancon, France) ,  Hiriart Jean-Baptiste (CHU de Bordeaux, Pessac, France) ,  Okusaka Takuji (National Cancer Center Hospital, Tokyo, Japan) ,  Morimoto Manabu (Kanagawa Cancer Center, Yokohama, Kanagawa, Japan) ,  Hsu Yanzhi (Eli Lilly, New York, NY, USA) ,  Abada Paolo B (Eli Lilly, Indianapolis, IN, USA) ,  Kudo Masatoshi (Kindai University, Osaka-Sayama, Japan)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 20  Issue： 2  Page： 282-296  Publication year： 2019 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Patients with advanced hepatoc...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0365851&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： *alpha fetoprotein ,  renal insufficiency ,  safety ,  *hepatoma ,  *phase 3 study ,  hypertension ,  *placebo ,  liver cirrhosis ,  drug therapy ,  effectiveness ,  aspartate aminotransferase ,  *double blind test ,  molecular targeting drug
Semi thesaurus term： 有害事象 ,  エンドポイント ,  予後不良 , 【Automatic Indexing@JST】

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Sorafenib

Terms in the title (9)： 進行肝細胞癌 ,  α-フェトプロテイン ,  REACH ,  患者 ,  ソラフェニブ ,  二重盲検 ,  プラセボ ,  対照 ,  第3相試験